A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cortisol levels. 2. the safety and tolerability of Lu AG13909. 3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).

NCT Number	NCT06471829
Lead Sponsor	H. Lundbeck A/S
Conditions	Cushing's Disease
Enrollment	18 participants
Start Date	2024-06-19
Primary Completion	2026-09-15 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-12